Compare e l f Beauty Inc (ELF) vs Merck & Co., Inc. (MRK) Price & Performance

ELF Beauty trades at $109.12, up 3.89% today, and is near its R3 resistance level of $109. The stock shows strong technical momentum with bullish moving averages, though RSI levels above 70 indicate potential overbought conditions. Fundamentally, the company reported revenue of $1.31 billion in 2025 with a net income of $112.09 million, and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength. Expansion into Europe via Sephora for the rhode brand and marketing initiatives like the 'Mirror Mix' album signal aggressive growth strategies.

The outlook for ELF is positive given earnings momentum and international expansion, but the high P/E ratio of 108.12 poses valuation risks. Analyst consensus is a 'Buy' with a price target of $95.91, below the current price, suggesting limited near-term upside. Key risks include competitive pressures in the beauty sector and sensitivity to consumer spending trends. Institutional buying activity, such as State Street Corp's increased stake, supports confidence in long-term growth.

Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.

The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.